Windtree Therapeutics’ (WINT) “Neutral” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their neutral rating on shares of Windtree Therapeutics (NASDAQ:WINT) in a report published on Wednesday,Benzinga reports. The brokerage currently has a $7.00 price objective on the stock.

Windtree Therapeutics Price Performance

NASDAQ WINT opened at $0.43 on Wednesday. The business has a fifty day moving average price of $0.85 and a two-hundred day moving average price of $3.75. Windtree Therapeutics has a fifty-two week low of $0.41 and a fifty-two week high of $18.89. The stock has a market capitalization of $3.86 million, a PE ratio of -0.03 and a beta of 0.54.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.